Sanderling Ventures Appoints Paul A. Grayson As a Director of Its San Diego Office

Mar 26, 2003, 00:00 ET from Sanderling Ventures

    SAN DIEGO, March 26 /PRNewswire/ -- Sanderling Ventures, one of
 California's oldest venture investment firms dedicated to building new
 biomedical companies, today announced the appointment of Paul Grayson as a
 Director in the San Diego office.  Most recently the chief executive officer
 and chairman with Senomyx, Mr. Grayson has been involved in early stage
 healthcare companies since 1987, in a variety of senior management and
 business development roles.
     "Paul and I have worked together with several companies over the years and
 I believe he has a proven track record of technical and business success,
 especially when it comes to deal making," said Tim Wollaeger, managing
 director of Sanderling's San Diego office.  "Sanderling's philosophy is to
 mentor and help grow successful companies and Paul can provide significant
 experience to our portfolio companies that are interested in finding corporate
 partners, thereby making our investments more valuable."
     "What I appreciate most about Sanderling is the firm's commitment to
 devoting substantial time to the start-up phase of its portfolio companies,"
 said Grayson.  "By joining Sanderling, I have the opportunity to work with a
 top-tier investment firm while still applying my experience to the development
 of our portfolio companies by participating in decision-making, strategic
 development, recruiting and other key business functions."
     Prior to founding Senomyx, a biotechnology start-up in San Diego,
 Mr. Grayson was employed by Aurora Biosciences Corporation, now part of Vertex
 Pharmaceuticals, from 1996 until 1999, most recently as senior vice president
 of corporate development.  While at Aurora, Mr. Grayson was responsible for
 business development, establishing collaborations with Bristol Myers Squibb
 Company, Eli Lilly and Company, Warner-Lambert Company, Merck & Co., Inc.,
 F. Hoffmann-La Roche Ltd. and Pharmacia & Upjohn, Inc.  He also directed
 Aurora's investor relations and corporate finance, including both private and
 initial public stock offerings.
     From November 1987 to April 1996, Mr. Grayson held various discovery
 research, marketing, finance and business development positions at Allergan,
 Inc., Gensia Inc. and Advanced Tissue Sciences, Inc.  Mr. Grayson received his
 B.S. in Biochemistry and Computer Science from the University of California,
 Los Angeles and his M.B.A. from the University of California, Irvine.
 Currently, Mr. Grayson also serves on the board of directors of Ambit
 Biosciences and DiscoveRx Corporation.
     The Sanderling office is located at 4401 Eastgate Mall, San Diego, CA
 92121.  The phone number is 858-550-6061.  For more information on Sanderling,
 visit the website at www.sanderling.com .
 
     ABOUT SANDERLING VENTURES
     Founded in 1979, Sanderling is one of the oldest investment firms
 dedicated to building new biomedical companies.  Sanderling and its principals
 play an active role in new ventures by providing seed and early-stage funding,
 contributing management leadership and administrative support, developing
 cost-control strategies to extend available dollars, supplying technical and
 regulatory expertise where needed, and offering the insight and perspective of
 those who have "done it before."  Since its inception, Sanderling has
 supported over 45 biomedical companies from very early stages through
 commercial development, earning consistently high rates-of-return on its
 venture investments.
 
     For further information please contact: Carin Canale of
 Atkins + Associates, +1-858-527-3498, for Sanderling Ventures
 
 

SOURCE Sanderling Ventures
    SAN DIEGO, March 26 /PRNewswire/ -- Sanderling Ventures, one of
 California's oldest venture investment firms dedicated to building new
 biomedical companies, today announced the appointment of Paul Grayson as a
 Director in the San Diego office.  Most recently the chief executive officer
 and chairman with Senomyx, Mr. Grayson has been involved in early stage
 healthcare companies since 1987, in a variety of senior management and
 business development roles.
     "Paul and I have worked together with several companies over the years and
 I believe he has a proven track record of technical and business success,
 especially when it comes to deal making," said Tim Wollaeger, managing
 director of Sanderling's San Diego office.  "Sanderling's philosophy is to
 mentor and help grow successful companies and Paul can provide significant
 experience to our portfolio companies that are interested in finding corporate
 partners, thereby making our investments more valuable."
     "What I appreciate most about Sanderling is the firm's commitment to
 devoting substantial time to the start-up phase of its portfolio companies,"
 said Grayson.  "By joining Sanderling, I have the opportunity to work with a
 top-tier investment firm while still applying my experience to the development
 of our portfolio companies by participating in decision-making, strategic
 development, recruiting and other key business functions."
     Prior to founding Senomyx, a biotechnology start-up in San Diego,
 Mr. Grayson was employed by Aurora Biosciences Corporation, now part of Vertex
 Pharmaceuticals, from 1996 until 1999, most recently as senior vice president
 of corporate development.  While at Aurora, Mr. Grayson was responsible for
 business development, establishing collaborations with Bristol Myers Squibb
 Company, Eli Lilly and Company, Warner-Lambert Company, Merck & Co., Inc.,
 F. Hoffmann-La Roche Ltd. and Pharmacia & Upjohn, Inc.  He also directed
 Aurora's investor relations and corporate finance, including both private and
 initial public stock offerings.
     From November 1987 to April 1996, Mr. Grayson held various discovery
 research, marketing, finance and business development positions at Allergan,
 Inc., Gensia Inc. and Advanced Tissue Sciences, Inc.  Mr. Grayson received his
 B.S. in Biochemistry and Computer Science from the University of California,
 Los Angeles and his M.B.A. from the University of California, Irvine.
 Currently, Mr. Grayson also serves on the board of directors of Ambit
 Biosciences and DiscoveRx Corporation.
     The Sanderling office is located at 4401 Eastgate Mall, San Diego, CA
 92121.  The phone number is 858-550-6061.  For more information on Sanderling,
 visit the website at www.sanderling.com .
 
     ABOUT SANDERLING VENTURES
     Founded in 1979, Sanderling is one of the oldest investment firms
 dedicated to building new biomedical companies.  Sanderling and its principals
 play an active role in new ventures by providing seed and early-stage funding,
 contributing management leadership and administrative support, developing
 cost-control strategies to extend available dollars, supplying technical and
 regulatory expertise where needed, and offering the insight and perspective of
 those who have "done it before."  Since its inception, Sanderling has
 supported over 45 biomedical companies from very early stages through
 commercial development, earning consistently high rates-of-return on its
 venture investments.
 
     For further information please contact: Carin Canale of
 Atkins + Associates, +1-858-527-3498, for Sanderling Ventures
 
 SOURCE  Sanderling Ventures